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Abstract
Increased glutamatergic neurotransmission appears to mediate the reinforcing properties of drugs 
of abuse, including ethanol (EtOH). We have shown that administration of ceftriaxone (CEF), a β-
lactam antibiotic, reduced EtOH intake and increased glutamate transporter 1 (GLT-1) expression 
in mesocorticolimbic regions of male and female alcohol-preferring (P) rats. In the present study, 
we tested whether CEF administration would reduce nicotine (NIC) and/or EtOH intake by adult 
female P rats. P rats were randomly assigned to 4 groups: (a) 5% sucrose (SUC) and 10% SUC 
[SUC], (b) 5% SUC + 0.07 mg/ml NIC and 10% SUC + 0.14 mg/ml NIC [NIC-SUC], 15% EtOH 
and 30% EtOH [EtOH] and (d) 15% EtOH + 0.07 mg/ml NIC and 30% EtOH + 0.14 mg/ml NIC 
[NIC-EtOH]. After achieving stable intakes (4 weeks), the rats were administered 7 concurrent, 
daily i.p. injections of either saline or 100 mg/kg CEF. The effects of CEF on intake were 
significant but differed across the reinforcers; such that ml/kg/day SUC was reduced by ~30%, 
mg/kg/day NIC was reduced by ~70% in the NIC-SUC group and ~40% in the EtOH-NIC group, 
whereas g/kg/day EtOH was reduced by ~40% in both the EtOH and EtOH-NIC group. The 
effects of CEF on GLT-1 expression were also studied. We found that CEF significantly increased 
GLT-1 expression in the prefrontal cortex and the nucleus accumbens of the NIC and NIC-EtOH 
rats as compared to NIC- and NIC-EtOH saline-treated rats. These findings provide further 
support for GLT-1-associated mechanisms in EtOH and/or NIC abuse. The present results along 
with previous reports of CEF’s efficacy in reducing cocaine self-administration in rats suggest that 
modulation of GLT-1 expression and/or activity is an important pharmacological target for treating 
polysubstance abuse and dependence.
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Introduction
Changes in glutamatergic neurotransmission affect many aspects of neuroplasticity 
associated with alcohol and drug dependence (Szumlinski et al., 2008, Kalivas and Volkow, 
2011, Uys and Reissner, 2011, Lenoir and Kiyatkin, 2013, Halbout et al., 2014, 
Wakabayashi and Kiyatkin, 2014). For example, neuroadaptations in the glutamatergic 
system appear to mediate ethanol tolerance, dependence, and withdrawal in animals and 
humans (Krystal et al., 2003, Albrecht and Buerger, 2009, Hermann et al., 2012). 
Additionally, the effects of ethanol withdrawal are linked to increases in extracellular 
glutamate concentrations in rats (Rossetti and Carboni, 1995). Ethanol-induced 
neuroadaptations of the glutamatergic system include alterations in N-methyl-D-aspartate 
(NMDA) and alpha-amino-3-hydroxyl-5-methyl-4-isoxale-propionate (AMPA) receptor 
activity (Grant et al., 1990, Sanna et al., 1993, Snell et al., 1996, Chen et al., 1997, Ary et 
al., 2012). For instance, rapid ethanol withdrawal results in phosphorylation and re-
localization of synaptic NMDA receptors (Clapp et al., 2010). Studies from our laboratories 
and others have consistently demonstrated that ethanol exposure or self-administration leads 
to increases in extracellular glutamate concentration within the mesocorticolimbic system 
(Ding et al., 2012, Ding et al., 2013, Das et al., 2015). In addition, ethanol-induced increases 
in extracellular glutamate concentrations are associated with enhanced sensitivity of nucleus 
accumbens (Acb) NMDA-receptor stimulation (Siggins et al., 2003).
Importantly, experimenter- or self-administered ethanol decreases glutamate uptake in the 
Acb (Melendez et al., 2005) and cerebral cortex of rats (Schreiber and Freund, 2000). 
Glutamatergic activity in the posterior ventral tegmental area (pVTA) is also implicated; 
such that a low dose of ethanol (0.5 g/kg, i.p.) increases glutamate, a middle dose (1.0 g/kg) 
has no effect, whereas a high dose (2.0 g/kg) decreases glutamate levels in this region (Ding 
et al., 2012). In work with alcohol-preferring (P) rats, an animal model of alcoholism (c.f., 
(Bell et al., 2012, Bell et al., 2014)), chronic ethanol drinking increases basal extracellular 
glutamate and decreases glutamate clearance in both the pVTA and the Acb (Ding et al., 
2013). Moreover, two weeks of ethanol deprivation restored both glutamate re-uptake and 
extracellular glutamate levels (Ding et al., 2013). Extracellular glutamate levels are regulated 
by several glutamate transporters located in neurons and glia (Gegelashvili and Schousboe, 
1997, Seal and Amara, 1999, Anderson and Swanson, 2000). Glutamate transporter 1 
[(GLT-1), or its human homolog, the excitatory amino acid transporter 2 (EAAT2)], is the 
primary transporter regulating removal of extracellular glutamate in the central nervous 
system (CNS) (Ginsberg et al., 1995, Danbolt, 2001, Mitani and Tanaka, 2003).
Second only to ethanol, tobacco/nicotine is the most abused substance in the United States 
and around the world. In the United States, approximately two thirds of individuals use 
ethanol and more than one quarter use tobacco (Falk et al., 2006). Their co-use is common 
as well, with more than 46 million co-users in the U.S., with co-use rates highest among 
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adolescents and young adults (Falk et al., 2006). Individuals dependent upon one are also at 
least 3 times more likely, than the general population, to be dependent upon the other (Grant 
et al., 2004). Thus, individuals who smoke tobacco are more likely to drink alcohol than 
those who do not smoke tobacco; and, individuals who drink alcohol are more likely to 
smoke tobacco than those who do not drink alcohol (Bobo and Husten, 2000, Falk et al., 
2006). Importantly, nicotine exposure also increases extracellular glutamate concentrations 
in the mesocorticolimbic reward circuit (Reid et al., 2000). Substantial evidence suggests 
that increases in extracellular glutamate concentrations are probably associated with 
downregulation of GLT-1, and possibly xCT, expression in the mesocorticolimbic reward 
system (Knackstedt et al., 2009, Knackstedt et al., 2010, Alhaddad et al., 2014a, Alhaddad et 
al., 2014b). Hence, the interaction between GLT-1 expression in mesocorticolimbic regions 
and nicotine-seeking behavior requires further investigation.
The role of GLT-1 in chemical dependency has been studied in drug abuse models, including 
studies investigating excessive ethanol intake. Functional activation of GLT-1 appears to 
reduce the rewarding effects of cocaine, morphine and methamphetamine (Nakagawa et al., 
2005). In addition, upregulation of GLT-1 activity by ceftriaxone, a beta-lactam antibiotic, 
attenuated cue-induced cocaine-seeking behavior (Sari et al., 2009, Knackstedt et al., 2010). 
Importantly, our laboratory has reported that upregulation of GLT-1 expression/activity by 
ceftriaxone results in a dose-dependent, long-lasting reduction in ethanol intake by adult 
male P rats (Sari et al., 2011). In the present study, we investigated the effects of up-
regulating GLT-1 expression, by ceftriaxone, on the maintenance of ethanol and/or nicotine 
intake by adult female P rats. Since ceftriaxone-induced reductions in ethanol intake by male 
P rats is associated with upregulation of GLT-1 expression in the prefrontal cortex (PFC) and 
Acb, the present study also assessed whether ceftriaxone-induced reductions in ethanol 
and/or nicotine intake by female P rats were associated with upregulation of GLT-1 
expression in these two brain reward regions as well.
Materials and Methods
Animals
Adult female P rats (~75 days of age at the start of the experiment) were used in this study. 
No more than 2 rats from a litter were included in any condition or interaction between 
conditions. This was done to avoid litter effects and increase the generalizability of the 
findings (Holson and Pearce, 1992). Rats were housed in a temperature- (21°C) and 
humidity- (50%) controlled vivarium which was maintained on a 12h reverse-light/dark 
cycle (lights on at 2200h). All experimental procedures were approved by the Institutional 
Animal Care and Use Committee of Indiana University School of Medicine and are in 
accordance with guidelines set by the Institutional Animal Care and Use Committee of the 
National Institutes of Health, and the Guide for the Care and Use of Laboratory Animals.
Drinking protocol and treatment
Subjects were group-housed until ~75 days old. At ~75 days old, the animals were single-
housed in hanging stainless steel cages. After adaptation to the caging, which included a 
Plexiglas® plate in each cage to reduce isolation and wire-mesh associated stress, the 
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animals were randomly assigned to one of four conditions. In the first condition, the animals 
were given continuous (24h/day) free-choice, concurrent access to 5% and 10% sucrose 
[SUC] for 5 weeks to serve as an appetitive control. The concentrations of sucrose were 
chosen for their high palatability. In the second condition, the animals were given continuous 
(24h/day) free-choice, concurrent access to 15% and 30% ethanol [EtOH] for 5 weeks. 
Multiple concentrations of ethanol yield higher levels of intake compared to access to a 
single concentration of ethanol [e.g., (Bell et al., 2003)], moreover, this effect is independent 
of rat line/strain or even rodent species [c.f., (Bell et al., 2014)]. In the third condition, the 
animals were given continuous (24h/day) free-choice, concurrent access to 5% sucrose and 
0.07 mg/ml nicotine along with 10% sucrose and 0.14 mg/ml nicotine [NIC-SUC] for 5 
weeks. In the fourth condition, the animals were given continuous (24h/day) free-choice, 
concurrent access to 15% ethanol and 0.07 mg/ml nicotine along with 30% ethanol and 0.14 
mg/ml nicotine [EtOH-NIC] for 5 weeks. The nicotine concentrations were chosen based on 
a previous study from our laboratory, which used multiple concentrations of nicotine as well 
as ethanol (Hauser et al., 2012).
Despite the reluctance to orally consume nicotine, our laboratory has found that when the 
nicotine solution is adulterated with either ethanol or sucrose P rats will readily ingest 
sufficient amounts of nicotine to attain blood nicotine and/or continine levels seen in 
tobacco-dependent individuals (Hauser et al., 2012). Although, the bitter taste of nicotine 
still modestly, albeit significantly, reduces ingestion levels for these reinforcers (ethanol and 
sucrose).
At the end of the 4th week of solution access, each condition was split into 2 dose groups for 
a ceftriaxone (0 vs. 200 mg/kg, injected intraperitoneally) treatment phase. Saline served as 
the vehicle. In animal models studying drug-seeking behavior and drug dependence 
performed in our laboratory and that of others has tested ceftriaxone at a dose of 200 mg/kg 
for the up-regulation of GLT-1. Hence, this treatment dose was selected for this study (Sari 
et al., 2009, Knackstedt et al., 2010, Sari et al., 2011, Ward et al., 2011, Fischer et al., 2013, 
Barr et al., 2015). Treatments were administered once-a-day for 7 consecutive days at the 
beginning of the dark-cycle, across the 5th week of solution access. The animals had ad 
libitum access to food and water throughout the experiment.
Brain harvesting
Twenty-four hours after the final injection brains were harvested from the animals for 
subsequent Western Blot analyses. This time-point coincided with lights out. We have found 
repeatedly that significantly less ethanol is consumed during the reduced activity period 
(lights on) for P rats. Thus, in general, negligible concentrations of ethanol are present in the 
blood and brain. The brains were removed flash-frozen and stored at −70°C. The PFC and 
Acb were subsequently micropunched using a cryostat maintained at −20°C, in order to keep 
the tissue frozen. After the brain regions were micropunched, they were returned to the 
−70°C freezer until GLT-1 protein levels were assayed with the Western blot procedure. 
Brains from a random subset of animals from each drinking-solution by ceftriaxone-
treatment condition were used for the Western Blot analyses.
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Western Blot analyses
Western blot procedures to examine the level of GLT-1 in the PFC and Acb were performed 
as described in previous studies (Sari et al., 2009, Sari et al., 2010, Sari et al., 2011). Briefly, 
proteins were loaded in 10-20% glycine gel (Invitrogen) and separated in a mini-cell 
apparatus. Proteins then were electrophoretically transferred onto a nitrocellulose 
membrane. The membrane was incubated in blocking buffer (3% milk in TBST, 50 mM Tris 
HCl; 150 mM NaCl, pH 7.4; 0.1% Tween20); and then incubated with primary antibody 
guinea pig anti-GLT-1 (Millipore) diluted 1:5000 in 3% milk in TBST overnight at 4°C. 
Membranes then were incubated with horseradish peroxidase (HRP)-labeled anti-guinea pig 
secondary antibody. The same membranes also were assessed for β-tubulin immunoblotting 
as a loading control. SuperSignal West Pico Chemiluminescence substrate (Pierce) was used 
to reveal HRP activity. Membranes then were exposed to Kodak BioMax MR film and 
developed using an SRX-101A developer. Immunoblots were analyzed using the MCID 
system. The data are presented as percentage ratios of GLT-1/β-tubulin, relative to saline-
control levels.
Statistical Analyses
Drinking-solution data—Daily measures of sucrose (g/kg/day), ethanol (g/kg/day), 
nicotine (mg/kg/day) and water (ml/kg) intake as well as body weights (g) were recorded 
during the 7-day ceftriaxone-treatment phase. Because the experimental design was not 
balanced across solutions (i.e., a sucrose-nicotine condition was used instead of a nicotine-
alone condition), three separate 2 × 2 × 7 (Test Solution by Dose by Test Day) mixed 
ANOVAs were conducted as omnibus analyses. Test Solution and Dose were the between-
subject factors and Test Day was the within-subjects factor. Water intake and body weight 
were also analyzed for each respective drinking-solution by ceftriaxone-treatment group. 
Appropriate simple effect analyses, using Protected Fisher’s LSD tests, followed significant 
higher-order effects. In order to control for possible inflations in alpha-error due to separate 
omnibus mixed ANOVAs, alpha was set at p ≤ 0.025 for all analyses.
Western blot data—Western blot data from the saline-treated group was converted to 
100% and the changes in expression of proteins, as a ratio to the loading control β-tubulin. 
The percentage ratios of GLT-1/β-tubulin in PFC and Acb were analyzed using independent 
one-sample t-test analyses versus 100% to determine changes in protein expression. The 
level of significance was set at p<0.05.
Results
The daily sucrose intakes were measured in sucrose only group (termed “Sucrose Only 
Solution”) and nicotine + sucrose group [termed “Sucrose + Nicotine Solution”]. From the 
nicotine + sucrose group, daily nicotine intake was also measured (termed Nicotine + 
Sucrose Solution”) as reported in Figure 1. A similar nomenclature has been employed for 
the ethanol + nicotine concurrent-consuming group of P rats, when depicting levels of 
nicotine versus ethanol consumed/kg body weight/day by this group.
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Sucrose Intake
The omnibus 2 × 2 × 7 (Test Solution by Dose by Test Day) mixed ANOVA on the sucrose 
consumption data revealed a significant Test Solution by Dose interaction [F(1,16) = 7.435, 
p = 0.015] as well as the main effects for Test Solution [F(1,16) = 325.346, p < 0.001] and 
Dose [F(1,16) = 14.344, p = 0.002]. As seen in Figure 1 (Top panels), the addition of 
nicotine significantly and precipitously (practically 10-fold) decreased sucrose intake and 
there were differential effects of ceftriaxone, such that the effect of ceftriaxone appears to be 
greater with the dual-reinforcer (sucrose + nicotine) solution compared with the single-
reinforcer sucrose solution, despite the possibility for a floor effect with the dual-reinforcer 
solution (Figure 1, top panels). When examining the sucrose only data, the 2 × 7 (Dose by 
Test Day) mixed ANOVA revealed a significant main effect for Dose [F(1,8) = 10.779, p = 
0.011] but no interaction indicating the relatively modest, but significant, reduction in 
sucrose consumption by ceftriaxone did not change significantly across days (Figure 1, Top 
left panel). When examining the sucrose intake data of animals consuming the sucrose + 
nicotine solution, the 2 × 7 (Dose by Test Day) mixed ANOVA revealed significant main 
effects for Dose [F(1,8) = 17.734, p = 0.003] and Test Day [F(1,6) = 6.855, p < 0.001] but no 
interaction indicating that ceftriaxone significantly reduced sucrose intake (Figure 1, Top 
right panel).
Nicotine Intake
The omnibus 2 × 2 × 7 (Test Solution by Dose by Test Day) mixed ANOVA on the nicotine 
consumption data revealed significant interactions for Test Solution by Dose [F(1,16) = 
6.221, p = 0.024] and Test Solution by Test Day [F(6,96) = 2.693, p = 0.018] as well as 
significant main effects for Dose [F(1,16) = 14.344, p = 0.002] and Test Day [F(6,96) = 
9.195, p < 0.001]. The 3-way interaction and Test Solution main effects approached 
significance (p = 0.039 and 0.030, respectively). As seen in Figure 1 (Middle panels), 
nicotine intake was higher when mixed with sucrose compared to ethanol; but, except for the 
first Test Day, ceftriaxone reduced nicotine intake to similar daily levels regardless of the 
adulterant (sucrose vs ethanol). When examining the nicotine intake data in the nicotine + 
sucrose solution, the 2 × 7 (Dose by Test Day) mixed ANOVA revealed significant main 
effects for Dose [F(1,8) = 17.654, p = 0.003] and Test Day [F(6,48) = 7.808, p < 0.001]. 
Figure 1 (Middle left panel) indicates that ceftriaxone significantly reduced nicotine intake 
in the presence of sucrose. When examining the nicotine intake data of animals consuming 
the nicotine + ethanol solution, the 2 × 7 (Dose by Test Day) mixed ANOVA only revealed a 
significant main effect for Dose [F(1,8) = 17.199, p = 0.003] indicating that (a) ceftriaxone 
significantly reduced nicotine intake and (b) there was no change in ceftriaxone’s effect 
across Test Days (Figure 1, Middle right panel).
Ethanol Intake
The omnibus 2 × 2 × 7 (Test Solution by Dose by Test Day) mixed ANOVA on the ethanol 
consumption data revealed a marginally significant 3-way Test Solution by Dose by Test 
Day interaction [F(6,96) = 2.507, p = 0.027] as well as significant main effects for Dose 
[F(1,16) = 29.805, p < 0.001] and Test Day [F(6,96) = 2.543, p = 0.025]. As with the sucrose 
+ nicotine data, the addition of nicotine decreased concurrent ethanol intake, but not nearly 
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to the extent seen with the sucrose solution (Figure 1, Top and Bottom panels). Also, as with 
the sucrose + nicotine data, ceftriaxone appears to be slightly more effective under the dual-
reinforcer condition (Figure 1, Bottom right panel). When examining the ethanol only data, 
the 2 × 7 (Dose by Test Day) mixed ANOVA revealed a significant main effect for Dose 
[F(1,8) = 13.039, p = 0.007]. As seen in Figure 1 (Bottom left panel), in general ceftriaxone 
was equally effective in reducing ethanol intake across Test Days. When examining the 
ethanol intake data of animals consuming the ethanol + nicotine solution, the 2 × 7 (Dose by 
Test Day) mixed ANOVA revealed a significant main effect for Dose [F(1,8) = 17.445, p = 
0.003], indicating that (a) ceftriaxone significantly reduced ethanol intake and (b) there was 
essentially no change in ceftriaxone’s efficacy across Test Days (Figure 1, Bottom right 
panel).
Effects of ceftriaxone on body weight (g), 2 hour and 24 hour water intake
When examining the rats that received sucrose as their test solution. Analyses of body 
weight, 2 hour and 24 hour water intake across test solution groups revealed no significant 
differences between ceftriaxone and saline during the treatment week (data not shown). 
When examining the rats that received sucrose-nicotine as their test solution. Analyses of 
body weight, 2 hour and 24 hour water intake across test solution groups revealed no 
significant difference in body weight; but, there were significant differences (p-values < 
0.025) in water consumption between treatment groups, such that the ceftriaxone-treated 
animals consumed substantially more water relative to their saline-treated counterparts (2 
hour: 20.4 ± 1.8 vs. 8.7 ± 1.0; 24 hour: 122.5 ± 9.5 vs. 67.1 ± 8.3 ml/day averaged across the 
week of treatment, respectively).
When examining the rats that received ethanol as their test solution. Analyses of body 
weight, 2 hour and 24 hour water intake across test solution groups revealed no significant 
difference in body weight; but, there were significant differences (p-values < 0.025) in water 
intake between treatment groups, such that the ceftriaxone-treated animals consumed more 
water relative to their saline-treated counterparts (2 hour: 27.6 ± 2.7 vs. 16.3 ± 1.7; 24 hour: 
117.7 ± 7.5 vs. 81.3 ± 4.6 ml/day averaged across the week of treatment, respectively).
When examining the rats that received ethanol-nicotine as their test solution. Analyses of 
body weight, 2 hour and 24 hour water intake across test solution groups revealed no 
significant difference in body weight and 2 hour water intake; but, there was a significant 
difference (p < 0.025) between treatment groups for 24 hour water intake, such that the 
ceftriaxone-treated animals consumed more than their saline-treated counterparts (118.4 
± 11.1 vs. 91.0 ± 4.0 ml/day averaged across the week of treatment, respectively).
Effects of ceftriaxone on GLT-1 expression in Acb and PFC across test solutions
We further determined the effects of ceftriaxone on GLT-1 expression in Acb and PFC of 
sucrose-nicotine consuming P rats. Independent one-sample t-test analyses versus 100% 
showed significantly increased expression of GLT-1 in Acb [t(4) = 3.498, p= 0.0249; Figure 
2A,B] and PFC [t(3) = 5.289, p= 0.0132; Figure 2A,B] of the nicotine-ceftriaxone group as 
compared to the nicotine-saline group. We also determined the effects of ceftriaxone on 
GLT-1 expression in Acb and PFC of ethanol-nicotine consuming P rats. Similar to the 
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sucrose-nicotine results, independent one-sample t-test analyses versus 100% showed 
increased expression of GLT-1 in Acb [t(4) = 3.170, p= 0.0339; Figure 2C,D] and PFC [t(4) 
= 6.139, p= 0.0036; Figure 2C,D] of the ethanol-nicotine-ceftriaxone group as compared to 
the ethanol-nicotine-saline group. Note that there were no significant differences in β-tubulin 
expression in PFC and Acb between all groups (p>0.5).
DISCUSSION
We report here that ceftriaxone treatment dramatically reduced the consumption of nicotine-
sucrose by adult female P rats. Ceftriaxone treatment also reduced the consumption of 
ethanol as well as the ethanol/nicotine solution by adult female P rats. In addition, the 
reductions in consumption of nicotine and ethanol were negatively associated with 
upregulation of GLT-1 in Acb and PFC of these rats. Also, as it has been observed 
repeatedly in our past studies, ceftriaxone has opposite effects on a reinforcer vs water, when 
the two are presented together, such that reinforcer intake decreases and water intake 
increases (Sari et al., 2011, Rao and Sari, 2014, Rao et al., 2015).
Studies from our laboratory have revealed that ethanol consumption for five weeks leads to 
an increase in extracellular glutamate concentrations within Acb (Das et al., 2015). We and 
others have reported that ceftriaxone, known to upregulate GLT-1 expression and function, 
attenuated cue-induced cocaine relapse (Sari et al., 2009, Knackstedt et al., 2010). This 
effect was associated with an increase in GLT-1 expression in PFC and Acb and was blocked 
by drugs that block GLT-1 (Fischer et al., 2013, Das et al., 2015). Importantly, we recently 
reported that male P rats treated with ceftriaxone showed a significant reduction in ethanol 
intake and attenuated relapse-like behavior, as well as upregulation of GLT-1 and another 
glial glutamate transporter, cystine/glutamate exchange transporter (xCT), expression in Acb 
and PFC (Sari et al., 2011, Rao and Sari, 2012, Qrunfleh et al., 2013, Sari et al., 2013, Rao 
and Sari, 2014). We also have shown that upregulation of GLT-1 with GPI-1046 significantly 
reduces ethanol intake by P rats (Sari and Sreemantula, 2012). GLT-1 expression was found 
to be downregulated in Acb, but not PFC, of male P rats after chronic consumption of 
ethanol compared to ethanolnaïve animals (Sari and Sreemantula, 2012, Sari et al., 2013). 
While in another study, xCT expression was downregulated in both PFC and Acb of ethanol 
consuming P rats compared to ethanol-naïve male P rats (Alhaddad et al., 2014a). In 
addition, we recently reported that (R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) 
reduced ethanol intake and upregulated GLT-1 protein expression in Acb of P rats (Alhaddad 
et al., 2014b). Although, it is unclear by what mechanism these compounds up-regulate the 
expression of GLT-1, we and others have reported that ceftriaxone, as well as MS-153, 
activate NF-κB via IκBα degradation and p65 translocation to the nucleus, which leads to 
increases in GLT-1 expression (Lee et al., 2008, Alhaddad et al., 2014b, Rao et al., 2015).
Regarding nicotine, administration of a non-selective GLT-1 blocker, mecamylamine and L-
trans-pyrolidine-2,4 dicarboxylic acid, exacerbated the increases in extracellular glutamate 
concentrations induced by nicotine (Reid et al., 2000). It is important to note that this study 
found that the effect of nicotine on glutamate release in Acb might not be directly associated 
with dopaminergic activity in the mesocorticolimbic circuit, which suggests the prominent 
role of glutamate transport during in vivo exposure to drugs of abuse. Pertinent to this 
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discussion, the role of GLT-1 has been investigated in a nicotine-self-administration 
paradigm, which showed that GLT-1 expression was downregulated in Acb following 
chronic nicotine self-administration (Knackstedt et al., 2009). Similarly, increases in 
extracellular glutamate concentrations and downregulation of GLT-1 expression were found 
after rats experienced a reinstatement of nicotine-seeking paradigm (Gipson et al., 2013). 
We and others have demonstrated the effectiveness of ceftriaxone in upregulating GLT-1 
expression, and putatively its function, which leads to a significant reduction in ethanol 
intake and cocaine seeking behavior (Sari et al., 2009, Knackstedt et al., 2010, Sari et al., 
2011, Rao and Sari, 2014, Rao et al., 2015). Importantly, ceftriaxone also reduced 
reinstatement of a conditioned place preference induced by nicotine exposure (Alajaji et al., 
2013). On a tangential note, a study demonstrated that ceftriaxone treatment facilitates the 
anti-nociceptive effects of nicotine and tolerance does not develop to this effect (Schroeder 
et al., 2011).
A few caveats need to be included on possible shortcomings of such study. First, the present 
study was conducted in female P rats and there is always the possibility for alteration of 
ethanol drinking behavior that might be associated with estrus cycle phase. In fact studies 
investigated the effects of estrous cycle phase in responses to female rats self-administering 
(Roberts et al., 1998). This study demonstrated that there were decrease of ethanol self-
administration in estrus and proestrus than diestrus in rats with synchronized cycles, 
however, there were no effects of estrous phase when the rats were allowed to cycle freely 
(Roberts et al., 1998). In addition, our laboratory has shown previously that the effects of 
ceftriaxone on ethanol drinking are similar between female and male P rats (Sari et al., 2011; 
2013). However, the role of sex differences, in nicotine intake, needs to be explored further. 
Regarding power of the statistical analyses, we must concede that the sample sizes (n=5/
condition, with a total of 40 animals used) are small and may have prevented our detecting 
more robust effects. We should knowledge that the small sample size could have caused 
some level of inaccuracy in the estimates of the mean and standard deviation. However, it is 
important to note that ceftriaxone was found to upregulate GLT-1 expression in PFC and 
Acb, and consequently reduced ethanol intake in adolescent and adult female P rats (Sari et 
al., 2013). Further research, with larger sample sizes is needed to replicate our beta lactam-
induced increases in GLT1 expression following nicotine-induced down-regulation of GLT1 
expression.
Overall, it appears that elevated extracellular glutamate concentrations in the 
mesocorticolimbic system are associated with oral, and putatively intravenous, intake of 
nicotine and alterations (decreases) in GLT-1 expression and/or function mediates this effect. 
Nevertheless, other neuronal glutamate transporters may also be involved. For example, a 
recent study revealed that nicotine exposure reduced EAAT3, excitatory amino acid 
transporter-3, activity (Yoon et al., 2014). These authors reported that this effect was 
dependent on multiple intracellular kinase signaling pathways. Given these findings and our 
previous work examining changes in xCT expression following ethanol drinking and 
ceftriaxone treatment, future research is needed to determine the role of other neuronal- and 
glial-associated glutamate transporters in the development of nicotine/tobacco dependence. 
Nevertheless, the present study provides novel insights, and supports the existing literature, 
regarding the effectiveness of ceftriaxone treatment in attenuating drug-seeking behavior, 
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presumably via upregulation of GLT-1 expression, in P rats which have a genetic 
predisposition for excessive ethanol intake.
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Highlights
➢ Ceftriaxone reduced nicotine intake by 70% in nicotine sucrose group.
➢ Ceftriaxone reduced nicotine intake by 40% in ethanol-nicotine group.
➢ CEF increased GLT-1 in PFC and Acb of nicotine and nicotine ethanol 
groups.
➢ GLT-1 as a target for the treatment of polysubstance abuse and dependence.
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Figure 1. 
The effects of 7 consecutive daily ceftriaxone (200 mg/kg, n = 5/treatment by test solution 
group) and saline (n = 5/treatment by test solution group) injections on average (± S.E.M.) 
intake of multiple test solutions by adult female alcohol-preferring P rats. Sucrose (g/kg/day) 
intakes by animals receiving the sucrose only test solution (5% and 10% available 
concurrently) are displayed in the left top panel; and sucrose intakes by animals receiving 
the sucrose + nicotine test solution (5% sucrose + 0.07 mg/ml nicotine and 10% sucrose 
+ 0.14 mg/ml nicotine available concurrently) are displayed in the right top panel. Nicotine 
(mg/kg/day) intakes by animals receiving the nicotine + sucrose test solution (5% sucrose 
+ 0.07 mg/ml nicotine and 10% sucrose + 0.14 mg/ml nicotine available concurrently) are 
displayed in the left middle panel; and nicotine intakes by animals receiving the nicotine + 
ethanol test solution (15% ethanol + 0.07 mg/ml nicotine and 30% ethanol + 0.14 mg/ml 
nicotine available concurrently) are displayed in the right middle panel. Ethanol (g/kg/day) 
intakes by animals receiving the ethanol only test solution (15% and 30% available 
concurrently) are displayed in the left bottom panel; and ethanol intakes by animals 
receiving the ethanol + nicotine test solution (15% ethanol + 0.07 mg/ml nicotine and 30% 
ethanol + 0.14 mg/ml nicotine available concurrently) are displayed in the right bottom 
panel. Within these panels test solution intake for each treatment day, the average across the 
7 days of treatment and the 7 day average converted to percent relative to the saline group 
are displayed. *, indicates a significant (p < 0.025) difference between the ceftriaxone- and 
saline-treated animals. Values are expressed as mean ± SEM.
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Figure 2. 
A) Effects of ceftriaxone on GLT-1 expression [GLT-1/β-tubulin (% of Control Group)] in 
nucleus accumbens (Acb) and prefrontal cortex (PFC) of nicotine consuming adult female P 
rats are depicted. B) As summarized in the bar graph, statistical analyses indicated 
significant differences between ceftriaxone-treated and saline-treated control animals 
(100%) in Acb (* p= 0.025) and PFC (* p= 0.013). C) Effects of ceftriaxone on GLT-1 
expression [GLT-1/β-tubulin (% of Control Group)] in Acb and PFC of nicotine and ethanol 
consuming adult female P rats are depicted. D) As summarized in the bar graph, statistical 
analyses indicated significant differences between ceftriaxone-treated and saline-treated 
animals (100%) in Acb (* p= 0.034) and PFC (** p= 0.004). Values are expressed as mean ± 
SEM, (n = 5 for each group except Nicotine-CEF-PFC, with n = 4).
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